135 related articles for article (PubMed ID: 31609151)
1. Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience.
Baidoun F; Chen D; Patnaik M; Gangat N; Begna K; Elliott M; Hogan W; Litzow M; Al-Kali A
Leuk Lymphoma; 2019 Oct; 60(10):2483-2487. PubMed ID: 31609151
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of dysplastic changes in acquired aplastic anemia: A systematic study of bone marrow biopsies in children and adults.
Marchesi RF; Velloso EDRP; Garanito MP; Leal AM; Siqueira SAC; Azevedo Neto RS; Rocha V; Zerbini MCN
Ann Diagn Pathol; 2020 Apr; 45():151459. PubMed ID: 32000075
[TBL] [Abstract][Full Text] [Related]
3. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
[TBL] [Abstract][Full Text] [Related]
4. Shifting of erythroleukemia to myelodysplastic syndrome according to the revised WHO classification: Biologic and cytogenetic features of shifted erythroleukemia.
Ryu S; Park HS; Kim SM; Im K; Kim JA; Hwang SM; Yoon SS; Lee DS
Leuk Res; 2018 Jul; 70():13-19. PubMed ID: 29729583
[TBL] [Abstract][Full Text] [Related]
5. Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis.
Margolskee E; Hasserjian RP; Hassane D; Tam W; Mathew S; Ok CY; Wang SA; Oak J; Arber DA; Orazi A
Am J Clin Pathol; 2017 Jul; 148(1):49-57. PubMed ID: 28927162
[TBL] [Abstract][Full Text] [Related]
6. [Re-evaluation of classification of myelodysplastic syndromes with low percentage bone marrow blasts].
Yu MH; Xu ZF; Li L; Nie L; Liu L; Zhang Y; Qin TJ; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):3-7. PubMed ID: 19563026
[TBL] [Abstract][Full Text] [Related]
7. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
8. Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution.
Nösslinger T; Reisner R; Koller E; Grüner H; Tüchler H; Nowotny H; Pittermann E; Pfeilstöcker M
Blood; 2001 Nov; 98(10):2935-41. PubMed ID: 11698274
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers of angiogenesis as prognostic factors in myelodysplastic syndrome patients treated with hypomethylating agents.
Kim CK; Han DH; Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Lee KT; Won JH; Hong DS; Kim HK
Leuk Res; 2016 Nov; 50():21-28. PubMed ID: 27639703
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia.
Matsushima T; Handa H; Yokohama A; Nagasaki J; Koiso H; Kin Y; Tanaka Y; Sakura T; Tsukamoto N; Karasawa M; Itoh K; Hirabayashi H; Sawamura M; Shinonome S; Shimano S; Miyawaki S; Nojima Y; Murakami H
Blood; 2003 May; 101(9):3386-90. PubMed ID: 12506028
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes.
Sharma P; Shinde SS; Damlaj M; Hefazi Rorghabeh M; Hashmi SK; Litzow MR; Hogan WJ; Gangat N; Elliott MA; Al-Kali A; Tefferi A; Patnaik MM
Leuk Lymphoma; 2017 Apr; 58(4):872-881. PubMed ID: 27687869
[TBL] [Abstract][Full Text] [Related]
12. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes.
Duong VH; Padron E; Al Ali NH; Lancet JE; Hall J; Kwok B; Zhang L; Epling-Burnette PK; List AF; Komrokji RS
Ann Hematol; 2018 Feb; 97(2):247-254. PubMed ID: 29167940
[TBL] [Abstract][Full Text] [Related]
14. Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics, and prognosis.
Maschek H; Kaloutsi V; Rodriguez-Kaiser M; Werner M; Choritz H; Mainzer K; Dietzfelbinger M; Georgii A
Ann Hematol; 1993 Mar; 66(3):117-22. PubMed ID: 8471656
[TBL] [Abstract][Full Text] [Related]
15. The effects of azacitidine on the response and prognosis of myelodysplastic syndrome and acute myeloid leukemia involving a bone marrow erythroblast frequency of >50.
Uchida T; Hagihara M; Hua J; Inoue M
Leuk Res; 2017 Feb; 53():35-38. PubMed ID: 28013105
[TBL] [Abstract][Full Text] [Related]
16. The incorporation of comorbidities in the prognostication of patients with lower-risk myelodysplastic syndrome.
Falantes JF; Márquez-Malaver FJ; Knight T; Calderón-Cabrera C; Martino ML; González J; Montero I; Espigado I; Pérez-Simón JA
Leuk Lymphoma; 2017 Aug; 58(8):1893-1902. PubMed ID: 27951729
[TBL] [Abstract][Full Text] [Related]
17. The myelodysplastic syndromes: analysis of prognostic factors and comparison of prognostic systems in 128 Chinese patients from a single institution.
Zhao WL; Xu L; Wu W; Yan H; Tang W; Hu J; Chen Y; Li JM; Zeng XY; Xiong SM; Shen ZX; Chen Z; Wang ZY; Chen SJ
Hematol J; 2002; 3(3):137-44. PubMed ID: 12111649
[TBL] [Abstract][Full Text] [Related]
18. An analysis of 97 previously diagnosed de novo adult acute erythroid leukemia patients following the 2016 revision to World Health Organization classification.
Qiu S; Jiang E; Wei H; Lin D; Zhang G; Wei S; Zhou C; Liu K; Wang Y; Liu B; Liu Y; Gong B; Gong X; Feng S; Mi Y; Han M; Wang J
BMC Cancer; 2017 Aug; 17(1):534. PubMed ID: 28793875
[TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count.
Chan GC; Wang WC; Raimondi SC; Behm FG; Krance RA; Chen G; Freiberg A; Ingram L; Butler D; Head DR
Leukemia; 1997 Feb; 11(2):206-11. PubMed ID: 9009082
[TBL] [Abstract][Full Text] [Related]
20. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).
Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Blanco ML; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu M; Ferrer A; Sanz GF; Florensa L
Am J Hematol; 2017 Jul; 92(7):614-621. PubMed ID: 28370234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
